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LETTERS TO THE EDITOR 
Does Atopic Dermatitis Result from Cytokine Dysregulation? 
To the Editor: 
I read with great interest the recent review article on atopic derma-
titis (AD) written by Dr. K. D. Cooper [1]. In this paper, the author 
introduced the helper T(Th)-cell activation pathways leading to 
either a strong immune cellular reaction (Th 1) through the release 
of interleukin (1L)-2 and interferon-y (IFN-y), or a vigorous anti-
body response (Th2) via the release of IL-4 and IL-5. Finally, he 
suggested that AD may be the result of an imbalance between these 
twO differentiation pathways, with an overexpression of the Th2, 
and an inhibition of the Th 1. This hypothesis has been verified by 
several studies . For instance, lesional T-cell clones showed a pro-
nounced dominance of the Th2 type [2]. Th2 cells are also predomi-
nant in neonates with familial history of atopy (Dr. S. Romagnani, 
personal communication). Here, I would like to further expose our 
current understanding of the modulation of the Th1/Th2 system 
through cytokines, which may be of interest if we believe that this 
system plays a major role in the development of AD. 
The direction taken by the CD4+ activated Th cells is selectively 
regulated by soluble mediators (Fig 1). Th 1 cells are promoted by 
IL-12, but are suppressed by IL-10. Th2 cells are activated by IL-4, 
and blocked by IL-12 and IFN-y. Although little is known about the 
respective potency of these cytokines on the system, IL-12 and 
IL-IO in addition to the more well-known IL-4 appear to be the key 
cytokines for steering an immune response towards Th 1 and Th2, 
respectively. Originally described as "natural killer stimulatory fac-
tor (NKSF)" and "cytotoxic lymphocyte maturation factor 
(CLMF)," IL-12 is a disulphide-Iinked heterodimer consisting of a 
40-kd and a 35-kd subunit [3]. It is produced mainly by monocytes/ 
macrophages, but also Iymphoblastoid and normal B cells. Its bio-
logic activities comprise the following: activation of lymphokine-
activated killer (LAK) and natural killer (NK) cells, proliferation of 
activated NK and T cells, and induction of the synthesis ofIFN-y by 
NK and T cells. Besides its action on the production of IFN-y, 
which leads to a suppression of IL-4 effects via down regulation of 
the IL-4 receptors, IL-12 has also IL-4 suppressive effects on its 
own, independent of IFN-y [4]. IL-10 is an 18.5-kd homodimer 
molecule produced by various types of cells, including Th2 cells, B 
cells, cells of the monocyte lineage, and keratinocytes [5]. It inhibits 
T-cell proliferation driven by either mitogen or an~i-C:D3. mono-
clonal antibodies in the presence of accessory cells, l11dlcatlllg that 
its action is mediated by the latter [6]. This inhibition is associated 
with reduced synthesis of the Th2 type secretory products IL-2 and 
IFN -yo IL-10 also seems to act as a mast cell growth factor in addi-
tion to IL-4 [5]. Finally, the recently discovered T-cell product 
IL-13 intervenes as an IL-4-like growth factor on monocytes and B 
cells [7]. 
Taken together, all these mediators form a potent regulatory 
network on T-cell activation. Their interactions explain the mutual 
inhibition of the Th 1 and Th2 responses, given that Th 1-cell-
derived products (e.g., IFN-y) reduce the Th2 response, whereas 
Th2-cell products (e.g., IL-10) decrease the Th 1 response. For this 
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Figure 1. Cytokine regulation of CD4+ T-cell activation pathways. 
reason, a defect in the metabolism of any of these may lead to a 
permanent imbalance of one type over the other such as overexpres-
sion ofTh2 to the detriment ofTh 1, as suspected in AD. Although 
this hypothesis remains to be demonstrated, it generates interest in 
defining new areas of research as well as new potential therapeutic 
targets, in a condition where treatment modalities are still poor. 
Patrick Dupuy 
Roche International Clinical Research Center 
Strasbourg, France 
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